IP Library Granted Patent US 7,183,105
Granted Patent B2
US 7,183,105 · App. 10/156,902 · Granted Feb 27, 2007

Eubacterial minicells and their use as vectors for nucleic acid delivery and expression

Assignee: Vaxiion Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,183,105
App. No.
10/156,902
Granted
Feb 27, 2007
Kind
B2
Abstract

Th invention provides compositions and methods for the production of achromosomal and anucleate cells useful for applications such as diagnositic and therapeutic uses, as well as research tools and agents for drug discovery.

Claims (17)

1. A fully intact minicell comprising a double stranded deoxyribose nucleic acid, wherein said nucleic acid comprises a mammalian expression sequence and a eubacterial expression sequence, each of which is independently operably linked to an open reading frame (ORF).

2. The minicell of claim 1 , wherein both the mammalian expression sequence and the eubacterial expression sequence are operably linked to the same ORF.

3. The minicell of claim 2 , wherein the protein encoded by said ORF comprises a eubacterial or a eukaryotic secretion sequence.

4. The minicell of claim 1 , wherein the mammalian expression sequence is operably linked to a first ORF and the eubacterial expression sequence is operably linked to a second ORF.

5. The minicell of claim 4 , wherein the mammalian expression sequence comprises a CMV promoter.

6. The minicell of claim 4 , wherein said second ORF encodes an Invasin polypeptide.

7. The minicell of claim 4 , wherein the protein encoded by said first ORF comprises eukaryotic secretion sequences and/or the protein encoded by said second ORF comprises eubacterial secretion sequences.

8. A method of introducing into and expressing a double stranded deoxyribose nucleic acid in an organism, comprising contacting a fully intact minicell to a cell of said organism in vivo, wherein said minicell comprises said double stranded nucleic acid.

9. The method of claim 8 , wherein said nucleic acid comprises a eukaryotic expression construct, wherein said eukaryotic expression construct comprises eukaryotic expression sequences operably linked to an ORF.

10. The method of claim 9 , wherein said ORF encodes a protein selected from the group consisting of a membrane protein, a soluble protein and a protein comprising eukaryotic secretion signal sequences.

11. The method of claim 8 , wherein said nucleic acid comprises a eubacterial expression construct, wherein said eubacterial expression construct comprises eubacterial expression sequences operably linked to an ORF.

12. The method of claim 11 , wherein the protein encoded by said ORF comprises eubacterial secretion sequences.

13. The method of claim 9 , wherein said eukaryotic expression construct is a mammalian expression construct.

14. The method of claim 13 , wherein said mammalian expression construct comprises a CMV promoter.

15. A method of generating an immunogenic response in a mammal comprising administering a fully intact minicell to said mammal in vivo, wherein said minicell comprises a double stranded nucleic acid open reading frame operably linked to an expression sequence, wherein said open reading frame encodes a polypeptide that stimulates an immunogenic response in said mammal when expressed.

16. The method of claim 15 , wherein said polypeptide is a viral antigen.

17. The method of claim 15 , wherein said polypeptide is a bacterial antigen.

Assignments (5)
ORGANIZATION CONVERSION Recorded Apr 30, 2015
From: VAXIION THERAPEUTICS, INC.
To: VAXIION THERAPEUTICS, LLC
Reel/Frame 035557/0644 →
SECURITY AGREEMENT Recorded Mar 21, 2013
From: VAXIION THERAPEUTICS INC.
To: WESTERN STATES INVESTMENT COMPANY, LLC
Reel/Frame 030062/0774 →
CHANGE OF NAME Recorded May 18, 2006
From: MPEX PHARMACEUTICALS, INC.
To: VAXIION THERAPEUTICS, INC.
Reel/Frame 017647/0201 →
CHANGE OF NAME Recorded Dec 6, 2004
From: MPEX BIOSCIENCE INC.
To: MPEX PHARMACEUTICALS, INC.
Reel/Frame 015429/0413 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2002
From: SABBADINI, ROGER A.; BERKLEY, NEIL; SURBER, MARK W.
To: MPEX BIOSCIENCES, INC.
Reel/Frame 013287/0387 →
Continuity (4)
Division 1015495100 · May 24, 2002
Provisional Application 6035984300 · Feb 25, 2002
Provisional Application 6029356600 · May 24, 2001
Related Publication 20030199088A1 · Oct 23, 2003